BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 31686784)

  • 21. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
    Kubota K; Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T
    Support Care Cancer; 2016 Sep; 24(9):4025-33. PubMed ID: 27129842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Vallejos W; Liang LW; Noga SJ; Rapoport BL
    Ann Oncol; 2016 Jan; 27(1):172-8. PubMed ID: 26449391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research.
    J Clin Oncol; 1995 Sep; 13(9):2417-26. PubMed ID: 7666102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
    Saito H; Yoshizawa H; Yoshimori K; Katakami N; Katsumata N; Kawahara M; Eguchi K
    Ann Oncol; 2013 Apr; 24(4):1067-73. PubMed ID: 23117073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
    Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: A double-blind, placebo-controlled, phase III randomized trial.
    Radhakrishnan V; Joshi A; Ramamoorthy J; Rajaraman S; Ganesan P; Ganesan TS; Dhanushkodi M; Sagar TG
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27551. PubMed ID: 30426714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
    Uchida M; Nakamura T; Makihara Y; Suetsugu K; Ikesue H; Mori Y; Kato K; Shiratsuchi M; Hosohata K; Miyamoto T; Akashi K
    Pharmazie; 2018 May; 73(5):304-308. PubMed ID: 29724299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.
    Li Y; Wan Y; Yang X; Chen P; Gui Y; He L; Xie Y; Tian J; Duan P; Liu G; Sun Y; Zhu J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):290. PubMed ID: 38836908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study.
    Yang LQ; Sun XC; Qin SK; Cheng Y; Shi JH; Chen ZD; Wang QM; Zhang HL; Hu B; Liu B; Zhang QY; Wu Q; Wang D; Shu YQ; Dong J; Han BH; Wang KM; Dang CX; Li JL; Wang HB; Li BL; Lu JG; Zhang ZH; Chen YX
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28393417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
    Rapoport BL; Jordan K; Weinstein C
    Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiemetic effects of granisetron and dexamethasone combination therapy during cisplatin-containing chemotherapy for head and neck cancer: dexamethasone dosage verification trial.
    Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Kimura M; Taguchi T; Yoshida T; Nagao J; Sakuma Y; Toth G
    Int J Clin Oncol; 2009 Aug; 14(4):337-43. PubMed ID: 19705245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study.
    Miyoshi T; Miyashita H; Matsuo N; Odawara M; Hori M; Hiraki Y; Kawanaka H
    Biol Pharm Bull; 2021; 44(10):1413-1418. PubMed ID: 34602550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial.
    Iihara H; Iwai M; Morita R; Fujita Y; Ohgino K; Ishihara T; Hirose C; Suzuki Y; Masubuchi K; Kawazoe H; Kawae D; Aihara K; Endo S; Fukunaga K; Yamazaki M; Tamura T; Kitamura Y; Fukui S; Endo J; Suzuki A
    Lung Cancer; 2024 Jun; 192():107801. PubMed ID: 38678830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial.
    Panahi Y; Saadat A; Sahebkar A; Hashemian F; Taghikhani M; Abolhasani E
    Integr Cancer Ther; 2012 Sep; 11(3):204-11. PubMed ID: 22313739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.
    Sigsgaard T; Herrstedt J; Christensen P; Andersen O; Dombernowsky P
    Support Care Cancer; 2000 May; 8(3):233-7. PubMed ID: 10789966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.